Nek8 Inhibitors

Chemical inhibitors of Nek8 include a range of compounds that target various kinases and cellular signaling pathways which Nek8 is known to be associated with. Staurosporine, a well-known kinase inhibitor, can inhibit Nek8 by directly targeting its kinase activity, which is crucial for its role in cell cycle regulation and ciliary functions. Similarly, 5-Iodotubercidin reduces the availability of phosphorylated adenosine substrates, which are necessary for kinases like Nek8 to function. Triciribine, although primarily known to inhibit the Akt pathway, can lead to a decrease in Nek8 activity by reducing phosphorylation within the cell, indicating an interconnection between these pathways and the activity of Nek8. Alsterpaullone, by competing with ATP binding sites, can impede Nek8's kinase activity, and Gö6976 disrupts cellular signaling by inhibiting Protein Kinase C, which could lead to a reduction in Nek8 activity through altered phosphorylation dynamics. Additionally, H-89, targeting Protein Kinase A, can alter the phosphorylation patterns within the cell and potentially reduce the activity of Nek8. Indirubin-3'-monoxime is capable of disrupting the kinase signaling network, and its broad-spectrum kinase inhibition may extend to Nek8, affecting its reliance on phosphorylation events. IC261, a Casein Kinase 1 inhibitor, can disrupt Nek8-involved signaling pathways, decreasing its kinase activity. PD 0332991, although selective for CDK4/6, can alter cell cycle progression, which is closely tied to Nek8's function, leading to its reduced activity. Roscovitine, another CDK inhibitor, by interfering with cell cycle regulatory kinases, can impinge upon the function of Nek8, given its role in cell cycle-related processes. Lastly, Tozasertib, an Aurora kinase inhibitor, disrupts mitotic processes which are integral to cell cycle regulation, indirectly leading to decreased Nek8 activity, since Nek8 has established roles in these cellular processes.